To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Integrilin (Eptifibatide) Significantly Improves Survival After Stent Implantation URL: http://www.pslgroup.com/dg/1EF08A.htm Doctor's Guide January 9, 2001
SOUTH SAN FRANCISCO, CA and KENILWORTH, NJ -- January 9, 2001 -- COR Therapeutics, Inc. and Schering-Plough Corporation reported the six-month results from the ESPRIT study with Integrilin® (eptifibatide) Injection which demonstrated a significant reduction in the incidence of death or myocardial infarction (heart attack) over the six months following intracoronary stent implantation from 11.5 percent with placebo to 7.5 percent with Integrilin (P=0.0015). This represents a highly significant 35 percent reduction in these adverse outcomes. Analysis of the results also showed that Integrilin significantly reduced the combined occurrence of death, myocardial infarction, or the need for repeat target vessel revascularization from 18.3 percent with placebo to 14.2 percent (P=0.0083). Myocardial infarction alone was significantly reduced by 33 percent (P=0.0047). Death alone was reduced by 43 percent from 1.4 percent with placebo to 0.8 percent with Integrilin (P=0.19). "These results clearly show that treating patients with eptifibatide during coronary stent angioplasty procedures provides a sustainable, long-term benefit," stated James E. Tcheng, MD, lead investigator for ESPRIT and Associate Professor of Medicine at Duke University Medical Center. "These findings, much awaited by the interventional cardiology community, corroborate the positive long-term effects previously reported with eptifibatide in the setting of non-ST-segment elevation acute coronary syndromes." The ESPRIT (Enhanced Suppression of Platelet Receptor GP IIb-IIIa using Integrilin Therapy) study was the first trial designed to assess the efficacy and safety of GP IIb-IIIa inhibitor therapy in patients undergoing non-urgent percutaneous coronary intervention (PCI) with the wide variety of intracoronary stents currently used in clinical practice. In ESPRIT, Integrilin was dosed using an experimental regimen of a 180 mcg/kg bolus, immediately followed by a 2 mcg/kg/min infusion, then followed by a second 180 mcg/kg bolus ten minutes later. The infusion was continued until hospital discharge for up to 18 to 24 hours. On February 4, 2000, an independent Data Safety Monitoring Committee (DSMC) stopped enrollment early in ESPRIT after an interim analysis of 1,758 patients revealed a highly statistically significant reduction in the incidence of death or heart attack at 48 hours with Integrilin as compared to placebo. Analysis of the entire cohort of 2,064 patients enrolled in ESPRIT at the time of study termination documented that the primary endpoint of death, myocardial infarction, need for urgent target vessel revascularization, or need for thrombotic bail-out therapy at 48 hours was reduced with Integrilin from 10.5 percent with placebo to 6.6 percent (P=0.0013). The incidence of death, myocardial infarction, or need for urgent target vessel revascularization at 30 days was reduced from 10.5 percent with placebo to 6.8 percent with Integrilin (P=0.0034). Consistent with previous clinical trials of GP IIb-IIIa inhibitors, major bleeding, primarily at the site for PCI catheter placement, was increased from 0.4 percent to 1.3 percent. Follow-up information was available for 98.5 percent of all patients at 6 months. Nearly 600,000 percutaneous coronary interventions are performed in the United States each year to restore blood flow through occluded arteries that supply oxygen to heart muscle. More than 60 percent of all PCI procedures employ the use of intracoronary stents, metal mesh structures that hold the artery open after the procedure. Although PCI and intracoronary stenting are generally successful at restoring blood flow and preventing the collapse of the artery, the deployment of the stent into the artery wall can result in the clumping of blood cells called platelets and the development of an intracoronary thrombus or blood clot. Because the thrombus can obstruct blood flow through the artery and thus deprive the heart muscle of oxygen supply, myocardial infarction (heart attack) or death can occur. Some patients may require urgent repeat intervention to reopen the artery. The vast majority of these thrombotic complications take place shortly following the PCI procedure. Integrilin helps prevent reocclusion of the stented artery by blocking certain receptors, known as GP IIb-IIIa, on platelets that are responsible for thrombus development. The effects of Integrilin are exerted at the time of the PCI procedure when the patient is at highest risk. Upon drug discontinuation, Integrilin is eliminated from the circulation, thus helping to reduce potential bleeding complications. Integrilin is currently indicated for the treatment of patients with acute coronary syndrome (unstable angina and non-Q-wave myocardial infarction), including patients who are to be managed medically and those undergoing percutaneous coronary intervention. It is also indicated for the treatment of patients at time of PCI. Integrilin is contraindicated in patients with a history of bleeding diathesis, or evidence of abnormal bleeding within the previous 30 days; severe hypertension (systolic blood pressure greater than 200 mm Hg or diastolic blood pressure greater than 110 mm Hg) not adequately controlled on antihypertensive therapy; major surgery within the preceding six weeks; history of stroke within 30 days, or any history of hemorrhagic stroke; current or planned administration of another parenteral GP IIb-IIIa inhibitor; platelet count less than 100,000 per cubic millimeter; serum creatinine greater than or equal to 4.0 mg/dL (in patients with serum creatinine levels between 2.0 mg/dL and 4.0 mg/dL, a 135 mcg/kg bolus and 0.5 mcg/kg/min infusion should be administered); dependency on renal dialysis; or known hypersensitivity to any component of the product. Bleeding is the most common complication encountered during Integrilin therapy. The majority of excess major bleeding events were localized at the femoral artery access site. Oropharyngeal, genitourinary, gastrointestinal and retroperitoneal bleeding were also seen more commonly with Integrilin compared to placebo. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.